Unchained Labs Buys Fourth Company
Taegen Clary, vice president of Marketing at Unchained, told IBO, “Freeslate adds around 60 employees to the Unchained Labs team, bringing our total up to 110 employees.” Regarding the expanded product lines, he said, “All of these products are perfect for the same customers working in biologics formulation labs and provide different pieces of information that get them to their goal, the most stable biologic.”
Pleasanton, CA 2/28/16—Unchained Labs, a supplier of high-throughput solutions for biologics formulation development and small molecule chemistry, has acquired Freeslate for an undisclosed amount. Freeslate develops configurable automated solutions for drug development. “Freeslate’s scale combined with Unchained Labs’ growth and capital creates a real juggernaut in the biologics formulation process,” commented Unchained Founder and CEO Tim Harkness. Unchained also announced a $25 million Series B financing as part of the transaction. Unchained has 110 employees and more than $25 million in annual revenues. This is Unchained Labs’s fourth acquisition in the past year, following the purchases of AVIA Biosystems, the Optim technology (see IBO 2/28/15) and Avid Nano (see IBO 10/31/15).
